Oral Cancer News

Michael Douglas Fights Oral Cancer

Source: The Science of Dentistry Actor Michael Douglas‘ recent revelation that he has stage IV oral cancer has highlighted the growing incidence of oral cancer, and experts say dentists can help stem the alarming increase of the disease by checking for it during routine examinations.The actor’s cancer includes a walnut-sized tumor at the base of his tongue, and he will require radiation therapy, chemotherapy, and surgery. Douglas says his doctors told him he has an 80% survival rate if it hasn’t spread to his lymph nodes. While tobacco was the prime cause of oral cancer in the past, recent studies have attributed the steady increase of the disease to the human papillomavirus (HPV). HPV are common viruses that cause warts. There are approximately 130 versions of HPV but only nine cause cancers, and the HPV16 version causes almost half of the oral cancers in the U.S., said Brian Hill, executive director of the Oral Cancer Foundation. “Tobacco is no longer the only bad guy,” he told DrBicuspid.com. “HPV16 is increasing in incidence as the causative etiology, and if it continues on this trend line, it will replace tobacco as the primary cause of oral cancers.” Dentists can play a key role in catching the disease in its early stages if they check for it during examinations. Most Americans have never even heard of oral cancer, but it’s not as rare or uncommon as people would like to think it is. This is why an opportunistic screening by the dental community [...]

Oral Cancer Foundation News Team - A2010-12-13T15:13:27-07:00December, 2010|OCF In The News, Oral Cancer News|

My dog saved my life, says Sunderland man

Source: Sunderland Echo By: Katy Wheeler John and Pauline Douglas were devastated when their dog Diesel had to be put down after developing cancer of the neck. But it was the late bull mastiff’s symptoms which helped John, 39, realise that he too had the disease. The dad-of-four, of Tunstall Bank, noticed a lump in his neck in February. And despite the fact he was told by doctors to rule out cancer, John’s experience with Diesel’s disease convinced him something was seriously wrong – and he pushed for further tests. His instincts were proved correct and John was diagnosed with cancer, which had spread to his neck, in April – just a week before his wedding day to wife Pauline, 41. John said: “Because of my age, the fact I don’t smoke and because I am a moderate drinker, I was told not to worry about cancer and that it was just an infection. “But what happened to Diesel set alarm bells ringing. “He had the same kind of lump in his neck that would swell up and down. We were told his wasn’t cancer to start with and it was only found late on. “Even though I was told by a specialist that I didn’t fit the criteria for cancer, the doubt was still niggling and I made such a song and dance that more tests were done.” As a result of John’s persistence, one of his tonsils was removed and a biopsy revealed the cancer, which had spread [...]

Charlotte Parker2017-03-29T19:08:21-07:00December, 2010|Oral Cancer News|

Manual Drainage for Lymphedema Investigated in First-Ever RCT

Source: Medscape Today By: Zosia Chustecka December 11, 2010 (San Antonio, Texas) — Manual lymph drainage (MLD) in the form of massage was not effective in preventing arm lymphedema in patients with breast cancer who had undergone axillary lymph node dissection. The results come from a randomized clinical trial in 160 patients with breast cancer, reported here today at the 33rd Annual San Antonio Breast Cancer Symposium. "This is a very nice study," commented session moderator Hiram Cody, MD, from the Memorial Sloan-Kettering Cancer Center in New York City. "This has been a data-free zone, and this [study] is a very nice addition," he added. The results were presented by Nele Devoogdt, from University Hospitals Leuven, in Belgium, who undertook the study as part of her doctoral thesis. She was the recipient of a scholarship awarded by the American Association for Cancer Research Translational Research Scholars and funded by Susan G. Komen for the Cure. Massage to Increase Lymph Drainage MLD is a kind of massage where the skin is stretched, Ms. Devoogdt explained. The theory is that it would help to prevent the development of lymphedema by increasing the resorption of lymph, increasing lymph transport, and creating collateral pathways to aid in lymph drainage. However, she pointed out that its effectiveness in preventing lymphedema has never been tested in a randomized controlled clinical trial. So this is what her group set out to investigate. They compared a program consisting of information and exercises therapy, with and without the addition [...]

Oral Cancer Foundation News Team - A2010-12-13T11:44:05-07:00December, 2010|Oral Cancer News|

More Indians chew tobacco blend, get oral cancer

Source: Boston.com By: Adi Narayan MUMBAI — Safiq Shaikh was 13 when he began chewing a blend of tobacco, areca nut, and spices that jolted him awake when his job at a textile loom got too dreary. Five years later, doctors in Mumbai lopped off his tongue to halt the cancer that was spreading through his mouth. Shaikh believed the fragrant, granular mixture he chewed, known in India as gutka, was a harmless stimulant and at first he ignored the milky lump growing inside his mouth. Now Shaikh is one of about 200,000 Indians diagnosed with a tobacco-related malignancy this year, said his surgeon, Pankaj Chaturvedi. India now has the highest number of oral cancers in the world, after a group of entrepreneurs known locally as “gutka barons’’ turned a 400-year-old tobacco product hand-rolled in betel leaves into a spicy blend sold for 2 cents on street corners from Bangalore to New Delhi. Sales of chewing tobacco, worth $4.6 billion in 2004, are on track to double by 2014, according to Datamonitor, a branch of the international research firm based in Hyderabad, India. The combination of tobacco and areca nut makes gutka and its hand-made ancestor, known as paan, addictive, scientists said. Areca nut is the fourth-most commonly used psychoactive substance in the world after tobacco, alcohol, and caffeine, according to the World Health Organization. “Now you have an industrial version of a traditional thing’’ spurring demand, said Chaturvedi, who works at Tata Memorial Hospital in Mumbai, Asia’s largest cancer [...]

Oral Cancer Foundation News Team - A2010-12-13T11:35:06-07:00December, 2010|Oral Cancer News|

Burgeoning market for smokeless tobacco products

Source: www.acsh.org Author: staff Now for some more good news on the harm reduction front: While cigarette sales have fallen by 17 percent since 2005 due to robust health campaigns and steeper taxes, smokeless tobacco products sales have grown by an annual rate of approximately 7 percent, reports The Chicago Tribune. The increase in sales of smokeless tobacco products can be partially attributed to their invisibility. For addicted smokers stuck in a smoke-free office environment all day long, these products relieve them of their nicotine craving. Economic factors have also been responsible for the rise in smokeless tobacco sales since a can of premium Swedish snus can run not much more than half the cost of a pack of Marlboro cigarettes in places where state, county and city excise taxes are high. Perhaps the most intriguing element to this story is that the use of smokeless tobacco products is increasing even though advertisers aren’t allowed to market them as a safer alternative to cigarettes. “I wonder how these people get the message,” ponders ACSH's Dr. Elizabeth Whelan. Even though medical experts agree that quitting tobacco altogether is the ideal scenario, scientists admit that smokeless tobacco products are much less harmful than cigarettes. But the potential benefit of these products, says ACSH's Dr. Gilbert Ross, is often overshadowed by anti-tobacco camps that focus on the possibility of increased risks of oral cancer from smokeless tobacco products. Dr. Ross notes that this risk “is essentially nil in the kinds of highly purified [...]

Oral Cancer Foundation News Team - A2010-12-12T10:03:39-07:00December, 2010|Oral Cancer News|

BioVex launches Phase 3 study on head and neck cancer treatment

Source: www.masshightech.com Author: James M. Connolly Woburn-based biotech company BioVex Inc. today said that it has launched a Phase 3 study of its OncoVEXGM-CSF as a treatment for patients with locally advanced squamous cell carcinoma of the head and neck. The study will be conducted at sites in the U.S. and U.K., and will enroll 528 previously untreated patients. The goal is to demonstrate a statistically significant increase in two-year, event-free survival for patients treated with chemoradition and with OncoVEXGM-CF. BioVex founder and chief technology officer Robert Coffin said in a press release, “The start of a second pivotal Phase 3 study is part of a broad planned development program for OncoVEX GM-CSF beyond our lead indication of metastatic melanoma.” BioVex has an operational commercial scale manufacturing facility in Woburn. It is developing biologics for the treatment of cancer and prevention of infectious disease. In addition to OncoVEXGM-CSF, the company has a second development program, ImmunoVEXHSV2, a vaccine for genital herpes that displayed complete protection in animal models. That vaccine is currently undergoing clinical testing in the U.K.

Oral Cancer Foundation News Team - A2010-12-12T09:57:29-07:00December, 2010|Oral Cancer News|

Tobacco company pays $5M in groundbreaking case

Source: www.ctlawtribune.com Author: Thomas B. Scheffey Kelly June Hill, Executrix, et al. v. U.S. Smokeless Tobacco: The Altria Group, successor to tobacco marketer United States Smokeless Tobacco of Greenwich, has settled for $5 million a lawsuit filed by the estate of a North Carolina man who died of tongue cancer. The worker, Bobby Hill, initially went to an Ashville, N.C., lawyer, who referred his case to Bridgeport’s Koskoff, Koskoff & Bieder. Partners Antonio Ponvert III and Christopher Bernard launched a state court wrongful death action in Connecticut. From the beginning, Ponvert said, Hill and his family wanted to draw attention to the danger of “dipping snuff” and to discourage youngsters from starting its addictive use. “It’s the first time a plaintiff has won a wrongful death chewing tobacco verdict or settlement in the history of the industry,” said Ponvert. Altria, based in Richmond, Va., also owns Philip Morris, and has a corporate policy of not settling any individual consumer cases, he added. Altria Group spokesman Steve Callahan said, “U.S. Smokeless Tobacco is honoring an agreement it made in this case prior to its acquisition by Altria….We have no current intention to settle cases like this in the future.” Historically, the tobacco industry has fiercely defended itself in the courts. And for decades, it denied that tobacco is addictive or a health risk. More recently, it has maintained that people know the risks of tobacco and they should take personal responsibility if they use it. In the industry, a no-settlement rule [...]

Oral Cancer Foundation News Team - A2010-12-12T09:51:00-07:00December, 2010|Oral Cancer News|

Electronic nicotine delivery systems: is there a need for regulation?

Source: http://tobaccocontrol.bmj.com/ Author: Anna Trtchounian, Prue Talbot Purpose: Electronic nicotine delivery systems (ENDS) purport to deliver nicotine to the lungs of smokers. Five brands of ENDS were evaluated for design features, accuracy and clarity of labeling and quality of instruction manuals and associated print material supplied with products or on manufacturers' websites. Methods: ENDS were purchased from online vendors and analyzed for various parameters. Results: While the basic design of ENDS was similar across brands, specific design features varied significantly. Fluid contained in cartridge reservoirs readily leaked out of most brands, and it was difficult to assemble or disassemble ENDS without touching nicotine-containing fluid. Two brands had designs that helped lessen this problem. Labeling of cartridges was very poor; labelling of some cartridge wrappers was better than labelling of cartridges. In general, packs of replacement cartridges were better labelled than the wrappers or cartridges, but most packs lacked cartridge content and warning information, and sometimes packs had confusing information. Used cartridges contained fluid, and disposal of nicotine-containing cartridges was not adequately addressed on websites or in manuals. Orders were sometimes filled incorrectly, and safety features did not always function properly. Print and internet material often contained information or made claims for which there is currently no scientific support. Conclusions: Design flaws, lack of adequate labeling and concerns about quality control and health issues indicate that regulators should consider removing ENDS from the market until their safety can be adequately evaluated. Authors affiliation: Department of Cell Biology and Neuroscience, University of [...]

Oral Cancer Foundation News Team - A2010-12-11T06:13:33-07:00December, 2010|Oral Cancer News|

When the state paid, people stopped smoking: study

Source: Reuters By: Maggie Fox When Massachusetts started paying for stop-smoking treatments, people not only kicked the habit but also had fewer heart attacks, researchers reported on Tuesday in the first study to show a clear payoff from investing in smoking prevention efforts. Smoking dropped by 10 percent among clients of Medicaid, the state health insurance plan for the poor, and nearly 40 percent of Medicaid patients who smoked used benefits to get nicotine patches or drugs to help them quit, the researchers said. The study -- which suggests states can save money from investing in efforts to cut smoking -- found the yearly rate of hospital admissions for heart attacks fell by 46 percent for Medicaid clients and 49 percent fewer of them were hospitalized for clogged arteries. "The dramatic decline in heart attack hospitalizations for smokers who used the benefit is stunning and demonstrates the effectiveness of tobacco treatment coverage that includes behavioral counseling and medicines approved by the Food and Drug Administration," American Heart Association CEO Nancy Brown, who was not involved in the research, said in a statement. Thomas Land and colleagues at the Massachusetts Tobacco Cessation and Prevention Program, as well as the Harvard Medical School, looked at hospital records for the study, published in the Public Library of Science journal PLoS Medicine. In July 2006, the Massachusetts Medicaid program, called MassHealth, began paying for drugs and other treatments to help smokers quit, including nicotine patches, gum and drugs. "Over 75,000 Medicaid subscribers used the [...]

Oral Cancer Foundation News Team - A2010-12-10T12:20:36-07:00December, 2010|Oral Cancer News|

Age is not a limiting factor for brachytherapy for carcinoma of the node negative oral tongue in patients aged eighty or older

Source: 7thspace.com Author: Hideya Yamazaki et al Purpose: To examine the role of brachytherapy for aged patients 80 or more in the trend of rapidly increasing number. Methods: We examined the outcomes for elderly patients with node negative oral tongue cancer (T1-3N0M0) treated with brachytherapy. The 21 patients (2 T1, 14 T2, and 5 T3 cases) ranged in age from 80 to 89 years (median 81), and their cancer was pathologically confirmed. All patients underwent definitive radiation therapy, with low dose rate (LDR) Ra-226 brachytherapy (n=4; median 70Gy), with Ir-192 (n=12; 70Gy), with Au-198 (n=1) or with high dose rate (HDR) Ir-192 brachytherapy (n=4; 60 Gy). Eight patients also underwent external radiotherapy (median 30 Gy). The period of observation ranged from 13 months to 14 years (median 2.5 years). We selected 226 population matched younger counterpart from our medical chart. Results: Definitive radiation therapy was completed for all 21 patients (100%), and acute grade 2-3 mucositis related to the therapy was tolerable for patients with good performance status. Local control (initial complete response) was attained in 19 of 21 patients (90%). The 2-year and 5-year local control rates were both 91%, (100% for T1, 83% for T2 and 80% for T3 tumors after 2 years). The cause-specific survival rate was 83% and the regional control rate 84% at the 2-years follow-up. However, 12 patients died because of intercurrent diseases or senility, resulting in overall survival rates of 55% at 2 years and 34% at 5 years. Conclusion: Age is not [...]

Oral Cancer Foundation News Team - A2010-12-10T09:00:06-07:00December, 2010|Oral Cancer News|